Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain

The study consisted of a cost-minimisation analysis since the findings from a multicentre randomised phase III trial showed that pegylated liposomal doxorubicin hydrochloride was at least as efficacious as topotecan. An economic model from the Spanish hospitals perspective was constructed to compare...

Descripción completa

Detalles Bibliográficos
Autores principales: Ojeda, B, de Sande, L M, Casado, A, Merino, P, Casado, M A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376947/
https://www.ncbi.nlm.nih.gov/pubmed/12966416
http://dx.doi.org/10.1038/sj.bjc.6601228

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376947/
https://www.ncbi.nlm.nih.gov/pubmed/12966416
http://dx.doi.org/10.1038/sj.bjc.6601228

Ejemplares similares